BI 1206

Drug Profile

BI 1206

Alternative Names: 6G 11; BI-1206

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioInvent International
  • Developer BioInvent International; University of Southampton
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen modulators; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 17 May 2018 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in Sweden (IV) (EudraCT2018-000444-26)
  • 23 Oct 2017 BioInvent International plans a phase I/IIa trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in first half of 2018
  • 01 Sep 2017 BioInvent has patents pending for BI 1206 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top